Immune checkpoint inhibitors (ICIs) that target the programmed death 1 receptor (PD-1) and programmed death-ligand 1 (PD-L1) have brought a durable long-term survival response to patients with malignant tumors. The gene discussed is CD274; the disease is cancer.